Cue Biopharma Inc (NASDAQ:CUE) shares shot up 8.1% during mid-day trading on Tuesday . The stock traded as high as $12.80 and last traded at $12.59, 153,200 shares changed hands during mid-day trading. An increase of 58% from the average session volume of 97,033 shares. The stock had previously closed at $11.65.
Several brokerages recently issued reports on CUE. ValuEngine lowered shares of Cue Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Zacks Investment Research upgraded shares of Cue Biopharma from a “hold” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Friday, November 15th.
The company has a debt-to-equity ratio of 0.10, a current ratio of 3.17 and a quick ratio of 3.17. The company has a market capitalization of $268.80 million, a PE ratio of -6.49 and a beta of 1.46. The stock’s 50 day simple moving average is $9.73 and its 200-day simple moving average is $8.39.
A number of large investors have recently modified their holdings of CUE. BlackRock Inc. increased its stake in Cue Biopharma by 21.3% during the second quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock worth $10,321,000 after purchasing an additional 201,986 shares during the period. Vanguard Group Inc. increased its stake in Cue Biopharma by 33.8% during the second quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock worth $5,504,000 after purchasing an additional 154,639 shares during the period. Rock Creek Group LP purchased a new stake in Cue Biopharma during the second quarter worth about $447,000. Millennium Management LLC purchased a new stake in Cue Biopharma during the third quarter worth about $117,000. Finally, Strs Ohio increased its stake in Cue Biopharma by 88.0% during the third quarter. Strs Ohio now owns 28,200 shares of the company’s stock worth $237,000 after purchasing an additional 13,200 shares during the period. Institutional investors own 26.45% of the company’s stock.
About Cue Biopharma (NASDAQ:CUE)
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Read More: What is Cost of Capital?
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.